Today, Samsara cells and tissues are enabling cutting edge research in the study of human biology and disease. In the hands of our partners and customers, our cells are contributing to the advancement of new tissue models, helping researchers identify promising new drugs that may treat life-threatening diseases, and breaking new ground in regenerative medicine.
The Foundation for Research and Science Development was established in 2009 and has the status of a Scientific Unit entered into the POLON MNiSW (Ministry of Science and Higher Education) system. The organization deals mainly with educational and research activities in the field of medical and biochemical sciences. It was created out of passion and the will to change the reality that surrounds us. The inspiration for establishing the Foundation was and is the scientific activity of Michał Wszoła MD, PhD., surgeon, transplantologist and, most of all, a dedicated doctor.
Founded in 2016, Qrons is a publicly traded, preclinical biotechnology company, developing advanced cell-based solutions to combat neurological injuries. While we are laser-focused on traumatic brain injury (TBI), our technology could potentially treat a wide range of neurodegenerative diseases.
BIOLIFE4D is a pioneering biotech company laser focused on leveraging advances in life sciences and tissue engineering to 3D bioprint a viable human heart suitable for transplant – lifesaving technology that gives patients the gift of time.
AstraZeneca established the BioVentureHub in 2014 as an open innovation ecosystem to further strengthen competitiveness and dynamism in the Scandinavian life science industry. Based on an innovative public-private partnership model and located at the heart of AstraZeneca Gothenburg, the BioVenturehub gives emerging biotech/medtech companies and academic groups from Sweden and abroad a unique opportunity to co-locate with - and tap into - the power of AstraZeneca’s world-class scientists and state-of-the-art lab facilities and infrastructure, and with each other.
SE3D.com is an EdTech startup, funded by the National Science Foundation, specializing in science education courseware and desktop 3D bioprinters for K9-14. Our unique curriculum and equipment is designed to prepare and propel the next generation of biomedical scientists, engineers and innovators.
CollPlant is a clinical-stage regenerative medicine company focused on developing and commercializing tissue repair products, initially for the orthobiologics and advanced wound care markets. Our products, two of which are in registration trials, are based on our proprietary plant-based collagen technology, which we believe is the only viable technology available for the production of recombinant type I human collagen. We believe that our rhCollagen, which is identical to the type I collagen produced by the human body, has significant advantages compared to currently marketed tissue-derived collagen. The attributes of our rhCollagen make it suitable for numerous tissue repair applications throughout the human body. We believe that the market opportunity for our current products utilizing our rhCollagen within the orthobiologics and advanced wound care markets exceeds $5 billion.
Collplant is a public company listed on the Tel Aviv Stock Exchange and on the OTCQX
The Institute for Bioengineering of Catalonia (IBEC) conducts excellent interdisciplinary research at the frontiers of engineering and life sciences in order to generate new knowledge by putting together fields like nanomedicine, biophysics, biotechnology, tissue engineering and the applications of health information technology.
MEDPRIN BIOTECH is a high-tech enterprise co-founded by outstanding biomedical scientists in September 2008, specialized in R & D, production and sales of regenerative medicine materials and regenerative implantable medical devices. MEDPRIN aims to become global leader in the field of implantable medical devices, relying on amazing capacity to provide excellent products for the patients worldwide based on biological 3D printing technology and nano-bionics technology, so MEDPRIN will accurately and efficiently manufacture more new implantable medical devices for human tissue recovery, replacement and regeneration, in accordance with the enterprise cultures featured in "innovation, cooperation and mutual love" and the quality policy to play a leading role in science & technology capacity and quality and constantly keep sound integrity to save more lives.
Our vision is to discover the brilliant idea in search of realization. We advocate the new formulation, the inspired concept, and the big idea that might change our patients' lives. We ask ourselves "what if?" and "can you imagine?" And you know what? We can.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. We have five approved products on the market today and are relentless in our pursuit of “medicines for life”®.
UT is recognized as one of the Top 10 Corporate Citizens in the field of U.S. drug manufacturing
Mayo Clinic's mission is to inspire hope and contribute to health and well-being by providing the best care to every patient through integrated clinical practice, education and research. Our primary value is "The needs of the patient come first."
Tissue Regeneration Systems™ (TRS™) is a start-up medical device company commercializing a breakthrough skeletal reconstruction and bone regeneration technology platform licensed from the Universities of Michigan and Wisconsin. Our technology addresses a broad range of clinical applications, and has been validated by comprehensive University, NIH and company-sponsored research initiatives spanning a period of well over a decade.
Founded in April 2007, 3D Biotek LLC is a biotechnology company located in New Jersey, USA. Using its Precision 3D Micro-Fabrication Technology and Advanced Bio-Manufacturing Technology, 3D Biotek is a leader in the research and development of novel 3-dimensional (3D) cell culture devices for stem cell/tissue engineering and drug discovery applications.
The North Carolina Biotechnology Center accelerates life science technology-based economic development through innovation, commercialization, education, and business growth.
NCBiotech is a private, non-profit corporation funded by the N.C. General Assembly. It is not a site for laboratory research; it works to support job creation in the life science industry.